Nivolumab

biologic · immune-hematologic · IV

Nivolumab, a biologic. Fully human IgG4 (S228P hinge-stabilised) mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → restores… IV half-life 25 d.

Fully human IgG4 (S228P hinge-stabilised) mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → restores anti-tumour T cell activity. Combined with ipilimumab (anti-CTLA-4) in melanoma, RCC, MSI-high CRC, and mesothelioma for synergistic response. Approved across melanoma, NSCLC, RCC, HCC, CRC, gastric, urothelial, head & neck, Hodgkin, and more.

Pharmacokinetics

• IV — t½ 25.0 d · F 100% · Vd 7.7 L

Sources: PMID:28019091, PMID:31402780